Navigation Links
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2012 Financial Results
Date:3/12/2013

LYNBROOK, N.Y., March 12, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S., today announced its financial results for the fourth quarter and full year ended December 31, 2012 and provided a corporate update.

"We are looking forward to the potential FDA approval of XIAFLEX for the treatment of Peyronie's disease followed by the anticipated commercial launch in the fourth quarter of this year, and believe in the strong commercial opportunity for XIAFLEX for this devastating disease," reflected Thomas L. Wegman, President of BioSpecifics. "We are also very pleased to announce today that we have completed enrollment in our Phase II clinical trial for XIAFLEX for human lipoma ahead of schedule, and that we remain on track to complete enrollment in our canine lipoma Phase II trial in the first half of 2013. We plan to report top-line data for both trials in the second half of 2013. We are also encouraged by the clinical progress Auxilium is making for XIAFLEX in Dupuytren's contracture patients with multiple palpable cords, cellulite and frozen shoulder. We anticipate reporting development progress for all of these indications beginning later this year."

Fourth Quarter & Full Year 2012 Financial ResultsBioSpecifics reported net income of $1.1 million for the fourth quarter ended December 31, 2012, or $0.17 per basic share and $0.16 per share on a fully diluted basis, compared to net income of $71,326, or $0.01 per basic and diluted common share for the same period in 2011. For the full year ended December 31, 2012, the Company reported net income of $3.0 million, or $0.47 per share on a basic and $0.43 per share on a fully diluted basis, compared to net income of $6.6 million, or $1.04 per share on a basic and $0.95 on a f
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
2. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2012 Financial Results on August 9, 2012
3. BioSpecifics Technologies Corp. To Present at Stifel Nicolaus Weisel Healthcare Conference 2012
4. BioSpecifics Technologies Corp. to Present at Two Upcoming Investor Conferences in September
5. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2012 Financial Results on November 8, 2012
6. BioSpecifics Technologies Corp. to Webcast, Live, at RetailInvestorConferences.com on December 6th
7. BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences
8. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2012 Financial Results on Tuesday, March 12, 2013
9. West Physics Consulting Teams with Mirion Technologies Dosimetry Services Division to Deliver Radiation Detection Services
10. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
11. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC ) today ... June 30, 2014. Financial Results for the Six ... revenue for the quarter ended June 30, 2014 increased to ... 30, 2013 primarily due to IMBRUVICA ® (ibrutinib) net ... for the six months ended June 30, 2014 increased to ...
(Date:7/31/2014)... VIEW, Calif. , July 31, 2014 /PRNewswire/ ... today provided an update on its pipeline and ... 2014, Alexza expects to initiate a Phase 2a ... is being developed for the management of patients ... two new Staccato -based product candidates for ...
(Date:7/31/2014)... , July 31, 2014 Rock Creek Pharmaceuticals, ... it has initiated the development of its lead molecule, ... that it has selected Quotient Clinical, The Translational Pharmaceutics ... (UK) to run its early development programs. ... Application (CTA) by the end of the third quarter ...
Breaking Medicine Technology:Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25Pharmacyclics Reports Second Quarter 2014 Results 26Pharmacyclics Reports Second Quarter 2014 Results 27Pharmacyclics Reports Second Quarter 2014 Results 28Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4
... March 30, 2011 Neurocrine Biosciences, Inc. (Nasdaq: ... Executive Officer of Neurocrine Biosciences, will be presenting at the ... The live presentation takes place on Wednesday, ... a.m. Pacific Time.  The presentation will be webcast and may ...
... 2011 CANTEL MEDICAL CORP. (NYSE: ... President, will be presenting at the Needham & Company, LLC ... 4:00 PM EDT on Wednesday, April 6, 2011 at the ... immediately following the presentation.  In addition, Mr. Segel will be ...
Cached Medicine Technology:
(Date:8/1/2014)... benefits of a cancer diagnosis may improve health outcomes ... conducted by a researcher at the University of Houston ... writing intervention is the writing instruction. Otherwise, writing is ... a journal can be therapeutic, but oftentimes we don,t ... or not," said Qian Lu, assistant professor and director ...
(Date:8/1/2014)... 01, 2014 Hot off the presses after ... category of the World’s Best Awards by Travel + ... celebration of National Relaxation Day (technically August 15). , ... MAJOR experts to help guests celebrate relaxation throughout the month ... for health and wellness to carve out time to relax ...
(Date:8/1/2014)... Mozes HealthDay Reporter FRIDAY, ... serve as a time-honored destination for a good cut and ... might also be the spot to tackle an often overlooked ... a novel partnership, the U.S. Centers for Disease Control and ... enlisted the help of barbershop staff to both discuss and ...
(Date:8/1/2014)... August 01, 2014 For years, proponents ... A recent study conducted by the Ohio ... too far behind in terms of their health and ... know what’s best for their baby. So does this ... Dr. Steven Shapiro , chair of Pediatrics at ...
(Date:8/1/2014)... GlobalDatas new report, "United ... provides key market data on the United ... value, in millions of US dollars, volume ... dollars) within market segments - Electrosurgical RF ... Plasma Coagulation Generators. , To view the ...
Breaking Medicine News(10 mins):Health News:Expressive writing may help breast cancer survivors 2Health News:Expressive writing may help breast cancer survivors 3Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 2Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 3Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 4Health News:Barbershops Join Fight Against High Blood Pressure in Black Men 2Health News:Barbershops Join Fight Against High Blood Pressure in Black Men 3Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 3Health News:United Kingdom Surgical Generators Market Size, Share, Analysis, Trends and Forecasts 2020 2Health News:United Kingdom Surgical Generators Market Size, Share, Analysis, Trends and Forecasts 2020 3
... and Drug Administration (FDA) has approved the NeuRx Diaphragm ... dependent on ventilators for breathing. The light-weight, battery-powered ... naturally, while eliminating the need for a power source ... was developed over the course of 20 years through ...
... safety program launched more than two years ago ... significantly improved communication between caregivers and patients and ... the program has found. , Children,s Hospital became ... with the Josie King Foundation to launch a ...
... proVision(TM) Now Manages Over 150,000 Identities, ANDOVER, ... the past six months, seven healthcare organizations have ... processes that eliminate the challenges of manual user ... (Nashville, TN) -- Baptist Health System (Birmingham, ...
... inspiring stories of Minnesotans who ... struggled to ... personally struggled to go smoke-free are sharing their,stories, from the time ... Their inspiring stories will be showcased in,ClearWay Minnesota,s traveling photo essay ...
... born by Caesarean section have a 50 % increased risk ... sections increase the risk even further. This is shown in ... registered at the Medical Birth Registry at the Norwegian Institute ... was to investigate the possible link between being born by ...
... CHAPEL HILL Psychosocial influences such as stress, depression ... studies involving people infected with HIV, yet they are ... individuals and the spread of AIDS, according to a ... , Now, a comprehensive update on those influences in ...
Cached Medicine News:Health News:FDA approves NeuRx diaphragm pacing system for use in spinal cord- injured patients 2Health News:Study finds Children's Hospital patient safety program improves caregiver/family communications 2Health News:Leading Healthcare Organizations Overwhelmingly Select Sentillion for User Provisioning 2Health News:Leading Healthcare Organizations Overwhelmingly Select Sentillion for User Provisioning 3Health News:In Smoke-Free Minnesota, Five Former Smokers Share Their Struggles With Fighting Addiction 2Health News:In Smoke-Free Minnesota, Five Former Smokers Share Their Struggles With Fighting Addiction 3Health News:In Smoke-Free Minnesota, Five Former Smokers Share Their Struggles With Fighting Addiction 4Health News:Caesarean sections associated with risk of asthma 2Health News:Psychosocial issues affect HIV/AIDS treatment outcomes: UNC researcher 2Health News:Psychosocial issues affect HIV/AIDS treatment outcomes: UNC researcher 3
... Parathyroid hormone (PTH) is synthesized ... secreted in response to decreased extracellular ... enhancing bone resorption and decreasing calcium ... into the circulation, intact PTH is ...
... the adrenal cortex and, to a lesser ... a precursor in testosterone and estrogen synthesis, ... at ~10% that of testosterone [1]. However, ... women, DHEA is an important androgen as ...
... steroid, is one of the most potent ... testosterone is secreted primarily by the testes ... peripheral conversion of androstenedione [2]. In adult ... 50% of serum testosterone is derived from ...
... Thyroxine (T4) is the primary active ... the thyroid gland [1]. T4 is synthesized ... iodide trapping by the follicular cells, (ii) ... substrate leading to formation of 3-monoiodotyrosine and ...
Medicine Products: